NOVEL GENE DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO286, PRO706, PRO1800, PRO4354, PRO6029, PRO9739, PRO20044, PRO28631 or...

Full description

Saved in:
Bibliographic Details
Main Authors SPARKS, MARY JEAN, PAYNE, BOBBY JOE, RANGEL, CAROLINA, BOLLINGER, KRISTI RAE, MINZE, LAURIE JEANETTE, DESAUVAGE, FREDERIC, GIRGIS, ROSEMARY, GREEN, LESLIE, EDWARDS, JOEL A, SHI, ZHENG-ZHENG, VOGEL, PETER, TANG, TRACY TZU-LING
Format Patent
LanguageEnglish
French
Published 27.03.2008
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO286, PRO706, PRO1800, PRO4354, PRO6029, PRO9739, PRO20044, PRO28631 or PRO34128 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities. La présente invention concerne des animaux transgéniques, de même que des compositions et des procédés concernant la caractérisation d'une fonction génétique. Spécifiquement, la présente invention fournit des souris transgéniques implantées avec des disruptions des gènes PRO286, PRO706, PRO1800, PRO4354, PRO6029, PRO9739, PRO20044, PRO28631 ou PRO34128. De telles études in vivo et de telles caractérisations peuvent fournir une identification valable et une découverte de thérapies et/ou de traitements utiles dans la prévention, l'amélioration ou la correction de maladies ou de dysfonctionnements associés à des disruptions génétiques comme des troubles neurologiques ; des troubles cardiovasculaires, endothéliaux ou angiogéniques ; des anomalies oculaires ; des troubles immunologiques ; des troubles oncologiques ; des anomalies ou des troubles métaboliques osseux ; des troubles métaboliques lipidiques ; ou des anomalies du développement.
Bibliography:Application Number: WO2007US66886